10.09
Corbus Pharmaceuticals Holdings Inc stock is traded at $10.09, with a volume of 425.85K.
It is up +0.10% in the last 24 hours and up +11.74% over the past month.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$10.08
Open:
$10.04
24h Volume:
425.85K
Relative Volume:
0.88
Market Cap:
$195.15M
Revenue:
$1.54M
Net Income/Loss:
$-84.53M
P/E Ratio:
-1.7353
EPS:
-5.8145
Net Cash Flow:
$-73.65M
1W Performance:
-0.79%
1M Performance:
+11.74%
6M Performance:
+33.47%
1Y Performance:
+4.78%
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
10.09 | 188.77M | 1.54M | -84.53M | -73.65M | -5.8145 |
|
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Corbus Pharmaceuticals (CRBP): Citadel entities and Kenneth Griffin disclose 1.1% stake - stocktitan.net
Price-Driven Insight from (CRBP) for Rule-Based Strategy - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Mizuho lowers Corbus Pharmaceuticals stock price target on model updates - Investing.com
Mizuho lowers Corbus Pharmaceuticals stock price target on model updates By Investing.com - Investing.com Australia
CRBP Insider Buying: Chief Business Officer Nishant Saxena Purch - GuruFocus
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $33 - Moomoo
Corbus Pharmaceuticals (NASDAQ:CRBP) Insider Buys 2,600 Shares of Stock - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Research Analysts Set Expectations for CRBP Q3 Earnings - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Corbus Pharmaceuticals (CRBP) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (NASDAQ:CRBP) CEO Yuval Cohen Sells 17,000 Shares of Stock - MarketBeat
Sean Moran Sells 12,000 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock - MarketBeat
Corbus Pharmaceuticals Holdings Inc Actuals & Estimates (NASDAQ:CRBP) - TradingView
Corbus Pharmaceuticals (NASDAQ:CRBP) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Corbus Pharmaceuticals Holdings Inc (CRBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock News Today - TradingKey
CRBP (NASDAQ: CRBP) insider plans 12,000-share sale via Stifel - stocktitan.net
CRBP (CRBP) holder files to sell 17,000 Nasdaq-traded shares - stocktitan.net
CRBP Maintained by Oppenheimer -- Price Target Lowered to $48.00 - GuruFocus
Oppenheimer Issues Pessimistic Forecast for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - MarketBeat
CRBP Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating - marketscreener.com
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $35 - Moomoo
HC Wainwright Has Lowered Expectations for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - MarketBeat
William Blair Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating - Moomoo
Form 8K Corbus Pharmaceuticals Holding For: 6 August By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals (NASDAQ: CRBP) ramps R&D to $51M as cash backs key trials - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update - The Manila Times
Corbus Pharmaceuticals (NASDAQ: CRBP) doubles Q2 loss while securing FDA clearance for Phase 3 trial - Stock Titan
Corbus Pharmaceuticals: Q2 Earnings Snapshot - marketscreener.com
Corbus Pharmaceuticals (CRBP) Earnings Date and Reports 2026 - MarketBeat
Corbus Pharmaceuticals (CRBP) Holds Gains as Biotech Momentum BuildsCall Wall - dars.gov.et
Corbus Pharmaceuticals Announces Last Patient Last Visit In Canyon-1 Study Of CRB-913 For The Treatment Of Obesity - marketscreener.com
Corbus Pharmaceuticals (CRBP) Completes Final Patient Visit in C - GuruFocus
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday - marketbeat.com
Corbus Pharma CMO Nicacio Leonardo Viana files initial beneficial ownership statement - Bitget
Obesity Treatment Study Reaches Final Visit; Corbus Data Expected in September - stocktitan.net
CRBP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity - Yahoo Finance
Corbus Pharmaceuticals Holdings Stock Price Forecast. Should You Buy CRBP? - StockInvest.us
Corbus Pharmaceuticals Holdings Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
Corbus Pharmaceuticals Holdings Inc (CRBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Corbus Pharmaceuticals (CRBP) Gains FDA Nod for Pivotal CRB-701 - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. initiates FDA-cleared registrational study for CRB-701 in oropharyngeal cancer - Traders Union
FDA clears Corbus registrational trial for head and neck cancer drug - Investing.com Nigeria
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cohen Yuval | Chief Executive Officer |
Aug 07 '26 |
Sale |
10.08 |
17,000 |
171,396 |
157,316 |
| Moran Sean F. | Chief Financial Officer |
Aug 07 '26 |
Sale |
10.08 |
12,000 |
120,971 |
84,694 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):